Tennessee Retina is an active participant in many national research trials. The efforts of our physicians and patients have led to the approval of many treatments now considered to be the standard of care, and our continuing involvement in clinical research offers access to new and potentially superior treatments to patients with sight-threatening conditions.
As with all patients, our clinical trial patients are very important to us, and we provide them with exceptional care and attention. Please contact your current eyecare provider to see if you may qualify for one of our studies, or contact one of our Clinical Trial staff members with any questions at (615) 983-6000.
Diabetes in the Eyes
NCT03610646 Clinical Trials.gov
A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema
RHINE GR40398 (Enrolling)
NCT03622593 Clinical Trials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema
Age-Related Macular Degeration (AMD)
NCT03577899 Clinical Trials.gov
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration.
TENAYA (Enrolling Soon)
NCT03823287 Clinical Trials.gov
A Phase III, multicenter, randomized, single-masked, active comparator controlled study to evaluate RO6867461 in patients with Neovascular Age-Related Macular Degeneration.
GALLEGO (Enrolling Soon)
NCT03972709 Clinical Trials.gov
A Phase II, multicenter, randomized, single-masked, sham injection-controlled study of the safety, tolerability, and evidence of activity of intravitreal injection of RO7171009 in patients with Geographic Atrophy secondary to age-related macular degeneration
NCT03891875 Clinical Trials.gov
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Elamipretide Solution in Subjects with Age-Related Macular Degeneration with Geographic Atrophy
NCT03748784 Clinical Trials.gov
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
NCT03178149 Clinical Trials.gov
A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration
ARCHWAY - GR40548 (Active, Enrollment Closed)
NCT03677934 Clinical Trials.gov
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
TRISTAR (Active, Enrollment Closed)
NCT03468296 Clinical Trials.gov
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
PORTAL - LADDER EXT GR40549 (Active, Enrollment Closed)
NCT03683251 Clinical Trials.gov
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
SCORE 2 (Active, Enrollment Closed)
NCT01969708 Clinical Trials.gov
Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
RAVEN (Enrolling soon)
NCT03810313 Clinical Trials.gov
An Eighteen-Month, Two-Arm, Randomized, Double- Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion